Investor Beat: JPMorgan's CEO Succession Chain Uncertain?

The Dow and S&P bounced back today, despite the latest round of housing data, which showed that new home sales fell 3.3% for the month of February, hitting a five-month low.

On Tuesday's edition of Investor Beat, host Chris Hill and Motley Fool analyst Morgan Housel discuss whether or not this puts an end to the housing market recovery. The guys discuss that while the harsh winter weather this year was definitely a factor here, the most important aspect to remember is that one month of data does not make a trend. Morgan still sees the housing recovery to be strong by several metrics, despite this blip.

Then, many have long considered Michael Cavanagh as the high-ranking executive who stood next in line at JPMorgan Chase for CEO, once Jamie Dimon stepped down. Now however, Cavanagh has been hired away from JPMorgan by private equity firm The Carlyle Group. Where will Dimon turn now for a successor? Chris and Morgan discuss the chain of succession at JPMorgan. Morgan notes that at these major financial institutions, one of the strongest assets they have is their high-quality employees, and that another toll of the institution facing so much litigation apart from the financial cost may be the drive for employees to go elsewhere, to firms that aren't making headlines.

Also, first quarter profits for McCormick & Company came in better than expected, and shares have risen on the news. Although the company hasn't been a market beater of late, Morgan thinks it's worth a second look. He discusses the spice maker, and talks about why "boring" stocks like McCormick sometimes make the best investments. Unlike the high flying, headline-grabbing stocks like Tesla Motors, McCormick doesn't need to constantly innovate, it can continue to make the same products that people will continue to need for decades to come. Morgan sees that as a key ingredient to outperformance over the long run.

And finally, Morgan takes a look at the iShares NASDAQ Biotechnology Index, and why he sees many tell-tale red flags that the biotech space is in a bubble right now. Morgan gives his insight on what these warning signs are, and whether or not the bubble could be near collapse.

Worried about the biotech bubble?
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2890218, ~/Articles/ArticleHandler.aspx, 8/22/2014 9:38:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement